Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Nasopharyngeal Carcinoma 7Breast Neoplasms 6Esophageal Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Liver Neoplasms 3Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Carcinoma, Non-Small-Cell Lung 2Adrenocortical Carcinoma 2Unresectable Gallbladder Cancer 1Turcot syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Non Squamous Non Small Cell Lung Cancer 1Nasopharyngeal Neoplasms 1Multiple Primary Lung Cancer 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Liver Diseases 1Leukemia, Myeloid, Acute 1Her-2 Negative Breast Cancer 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1camrelizumab 1apatinib 1Nivolumab 1Mitotane 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Floxuridine 1FAPI-46 1Dexamethasone 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adrenal Gland Neoplasms × camrelizumab × Clear all
NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

West China Hospital

Phase 2 Recruiting
28 enrolled
Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡